We engineer proteins that control the operating system of biology.
Key people at Epinoma.
Epinoma was founded in 2020 by Zhijian Li (Founder) and Varun Govil (Founder).
Epinoma is a biotechnology company that engineers proteins to control the "operating system" of biology by targeting epigenetic mechanisms—chemical modifications that regulate gene expression without altering DNA sequences. Their flagship product, EpiAmp, is a methylation-preserving amplification technology that enables highly sensitive and reliable detection of epigenetic signals, particularly useful for early-stage cancer detection and minimal residual disease monitoring. Epinoma serves researchers, diagnostic developers, and ultimately clinicians, addressing the critical problem of noisy and inefficient current epigenetic detection methods. The company has demonstrated strong growth momentum since its founding in 2020, gaining attention from major sequencing and diagnostic players and advancing toward commercial-grade applications[1][2][5].
Founded in 2020 by Varun Govil and Zhijian Li, Epinoma emerged from academic innovation at the University of Chicago, where foundational intellectual property was licensed through the Polsky Center for Innovation and Entrepreneurship. Govil brings a background in translational medicine and biotech development, while Li has expertise in chemistry and biomedical science focused on diagnostic innovation. The idea originated from the need to improve epigenetic detection methods, particularly methylation analysis, which is crucial for understanding disease states like cancer. A pivotal moment was the development of EpiAmp, which preserves methylation during DNA amplification, overcoming limitations of existing technologies and enabling more accurate epigenetic profiling[1][2].
Epinoma rides the growing trend of precision medicine and epigenetics, a field gaining momentum due to its potential to revolutionize disease detection and treatment by reading and modulating gene expression patterns. The timing is critical as advances in sequencing technologies and AI analytics create demand for high-quality epigenetic data. Market forces favor solutions that improve early cancer detection and patient stratification, areas where epigenetic markers like methylation are key. By providing foundational tools that enhance epigenetic measurement, Epinoma influences the broader biotech ecosystem, enabling new diagnostics, therapeutics, and data-driven biological insights[2][5].
Looking ahead, Epinoma is poised to expand its impact by further commercializing EpiAmp and developing additional epigenetic tools that could transform diagnostics and epi-therapeutics. Trends such as AI integration in healthcare, growing emphasis on early disease detection, and personalized medicine will shape its trajectory. As the company scales, it may become a cornerstone in the epigenetics ecosystem, enabling more precise, data-driven interventions and potentially reshaping how diseases like cancer are detected and treated. This aligns with their mission to engineer proteins that control biology’s operating system, unlocking new paradigms in medicine[2][5].
Key people at Epinoma.
Epinoma was founded in 2020 by Zhijian Li (Founder) and Varun Govil (Founder).
